Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1895412 | 0.98 | ADORA3 (0.48) | ADORA3ADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL38655985 | 0.83 | DHFR (0.51) | ADORA3ADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL26968497 | 0.81 | ADORA3 (0.62) | ADORA3ADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL4153044 | 0.75 | GAA (0.61) | ADORA3ADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL29459254 | 0.74 | PI4KA (0.64) | ADORA3ADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL9175737 | 0.74 | PI4KA (0.64) | ADORA3ADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL42351 | 0.74 | NOS1 (0.55) | ADORA3ADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL1811572 | 0.73 | ALDH1A1 (0.53) | ADORA3ADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL8211717 | 0.72 | KDM4E (0.49) | KDM4EHPGDALDH1A1MAPTGAA | |
| SCHEMBL29108569 | 0.72 | ADORA3 (0.43) | ADORA3ADORA2AADORA2BADORA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2334 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| US-11939582-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | ROGCON, INC. (US) | 2024-03-26 | — | — | US | claimed |
| CN-117715942-A | Enhanced targeting using antibody-oligonucleotide conjugates | 代码生物疗法公司 | 2024-03-15 | — | — | CN | claimed |
| EP-4330397-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | claimed |
| EP-4301859-A1 | ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Code Biotherapeutics, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| WO-2023196944-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2023192885-A2 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023150716-A2 | METHODS FOR THE TREATMENT OF SCN2A-RELATED DISORDERS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2022263569-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-22 | — | — | WO | claimed |
| EP-4105328-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | claimed |
| US-20090275133-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| US-7223849-B1 | Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth | GENESENSE TECHNOLOGIES INC. (CA) | 2007-05-29 | — | — | US | claimed |
| US-7087580-B2 | Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth | GENESENSE TECHNOLOGIES, INC. (CA) | 2006-08-08 | — | — | US | claimed |
| US-7067497-B2 | Modulation of telomere length by oligonucleotides having a G-core sequence | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-27 | — | — | US | claimed |
| US-20060024727-A1 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | claimed |
| EP-1153128-B1 | ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS OF RIBONUCLEOTIDE REDUCTASE | GENESENSE TECHNOLOGIES INC (CA) | 2005-11-09 | — | — | EP | claimed |
| EP-0917569-B1 | ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS OF RIBONUCLEOTIDE REDUCTASE | GENESENSE TECHNOLOGIES INC (CA) | 2005-11-09 | — | — | EP | claimed |
| US-20040049022-A1 | Composition & methods for treatment and screening | NYCE JONATHAN W (US) | 2004-03-11 | — | — | US | claimed |
| WO-2004011613-A2 | COMPOSITION & METHODS FOR TREATMENT AND SCREENING | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| US-6566514-B1 | Antisense oligonucleotides for use in the treatment of tumors | GENESENSE TECHNOLOGIES INC. (CA) | 2003-05-20 | — | — | US | claimed |